目的研究醒脑静注射液对高血压脑出血患者一氧化氮(NO)、胰岛素样生长因子-1(IGF-1)和巨噬细胞转移抑制因子(MIF)的影响。方法选择2012年1月至2014年10月在我院治疗的140例高血压脑出血且均成功进行了开颅或引流手术患者,随机分为对照组...目的研究醒脑静注射液对高血压脑出血患者一氧化氮(NO)、胰岛素样生长因子-1(IGF-1)和巨噬细胞转移抑制因子(MIF)的影响。方法选择2012年1月至2014年10月在我院治疗的140例高血压脑出血且均成功进行了开颅或引流手术患者,随机分为对照组(72例)和试验组(68例)。对照组,静脉注射5%的葡萄糖注射液,每次280 m L,1次/天;试验组,在对照组的基础上,静脉滴注醒脑静注射液30 m L,1次/天,疗程15 d。通过硝酸还原酶法检测NO水平,酶联免疫吸附法检测IGF-1水平和放射免疫分析法检测MIF的表达水平。结果试验组总有效率为88.24%,显著高于对照组的72.22%(P<0.05)。试验组NO水平为(52.22±10.78)μmol·L^(-1)、IGF-1水平为(61.90±10.94)nmol·L^(-1),显著高于对照组患者的NO水平(36.23±8.14)μmol·L^(-1)和IGF-1水平(40.64±10.42)nmol·L^(-1);试验组患者的MIF水平为(44.34±12.52)ng·L^(-1),明显比对照组患者的MIF水平低(均P<0.05)。试验组患者并发症例数明显低于对照组(P<0.05)。结论醒脑静注射液不仅可以提高患者疗效,减少患者术后并发症发生,还可以升高血清IGF-1和NO的表达水平,降低血清MIF水平,对患者病情改善有明显促进作用。展开更多
AIM: To investigate the clinical values of serum free insulin-like growth factor Ⅱ (IGF-Ⅱ) levels and IGF-Ⅱ mRNA in hepatocellular carcinoma (HCC) tissues and peripheral blood for diagnosis of HCC and monitoring of...AIM: To investigate the clinical values of serum free insulin-like growth factor Ⅱ (IGF-Ⅱ) levels and IGF-Ⅱ mRNA in hepatocellular carcinoma (HCC) tissues and peripheral blood for diagnosis of HCC and monitoring of extrahepatic metastasis.METHODS: Total RNAs were extracted from HCC tissues or peripheral blood mononuclear cells from patients with HCC, liver diseases devoid of cancer, non-hepatic tumors,and healthy controls, respectively. IGF-Ⅱ cDNAs were synthesized through random primers and reversetranscriptase, amplified by polymerase chain reaction (PCR), and confirmed by DNA sequencing analysis. Serum free IGF-Ⅱ levels in patients with different liver diseases were analyzed by an enzyme-linked immunosorbent assay.RESULTS: The amplified fragments of IGF-Ⅱ mRNA by RT-PCR were identical to originally designed ones with a size of 170 bp and confirmed by sequencing analysis.The dilution experiments revealed that the lowest sensitivity of our system was 2 ng/L of total RNA. The positive frequencies of IGF-Ⅱ mRNA were 100% in HCC tissues,53.3% in para-cancerous tissues, and 0% in non-cancerous tissues, respectively. The serum free IGF-Ⅱ levels were significantly higher in HCC than those in chronic hepatitis or liver cirrhosis. The positive frequency of circulating IGF-Ⅱ mRNA was 34.2% in HCC, no amplified fragment was found in other liver diseases, extrahepatic tumors,and normal controls, respectively. The circulating IGF-Ⅱ mRNA correlated with the stage of HCC, and its positive rate was 100% in HCC with extrahepatic metastasis and 35.5% in HCC with AFP-negative. No significant correlation was found between tumor sizes and circulating IGF-Ⅱ mRNA fragment.CONCLUSION: The abnormal expressions of free IGF-Ⅱ and IGF-Ⅱ mRNA are useful tumor markers for HCC diagnosis, differentiation of extrahepatic metastasis and monitoring postoperative recurrence.展开更多
文摘目的研究醒脑静注射液对高血压脑出血患者一氧化氮(NO)、胰岛素样生长因子-1(IGF-1)和巨噬细胞转移抑制因子(MIF)的影响。方法选择2012年1月至2014年10月在我院治疗的140例高血压脑出血且均成功进行了开颅或引流手术患者,随机分为对照组(72例)和试验组(68例)。对照组,静脉注射5%的葡萄糖注射液,每次280 m L,1次/天;试验组,在对照组的基础上,静脉滴注醒脑静注射液30 m L,1次/天,疗程15 d。通过硝酸还原酶法检测NO水平,酶联免疫吸附法检测IGF-1水平和放射免疫分析法检测MIF的表达水平。结果试验组总有效率为88.24%,显著高于对照组的72.22%(P<0.05)。试验组NO水平为(52.22±10.78)μmol·L^(-1)、IGF-1水平为(61.90±10.94)nmol·L^(-1),显著高于对照组患者的NO水平(36.23±8.14)μmol·L^(-1)和IGF-1水平(40.64±10.42)nmol·L^(-1);试验组患者的MIF水平为(44.34±12.52)ng·L^(-1),明显比对照组患者的MIF水平低(均P<0.05)。试验组患者并发症例数明显低于对照组(P<0.05)。结论醒脑静注射液不仅可以提高患者疗效,减少患者术后并发症发生,还可以升高血清IGF-1和NO的表达水平,降低血清MIF水平,对患者病情改善有明显促进作用。
基金Supported by a grants-in-aid from the Key Project of Medical Science from Jiangsu Province, China, No. RC2003100
文摘AIM: To investigate the clinical values of serum free insulin-like growth factor Ⅱ (IGF-Ⅱ) levels and IGF-Ⅱ mRNA in hepatocellular carcinoma (HCC) tissues and peripheral blood for diagnosis of HCC and monitoring of extrahepatic metastasis.METHODS: Total RNAs were extracted from HCC tissues or peripheral blood mononuclear cells from patients with HCC, liver diseases devoid of cancer, non-hepatic tumors,and healthy controls, respectively. IGF-Ⅱ cDNAs were synthesized through random primers and reversetranscriptase, amplified by polymerase chain reaction (PCR), and confirmed by DNA sequencing analysis. Serum free IGF-Ⅱ levels in patients with different liver diseases were analyzed by an enzyme-linked immunosorbent assay.RESULTS: The amplified fragments of IGF-Ⅱ mRNA by RT-PCR were identical to originally designed ones with a size of 170 bp and confirmed by sequencing analysis.The dilution experiments revealed that the lowest sensitivity of our system was 2 ng/L of total RNA. The positive frequencies of IGF-Ⅱ mRNA were 100% in HCC tissues,53.3% in para-cancerous tissues, and 0% in non-cancerous tissues, respectively. The serum free IGF-Ⅱ levels were significantly higher in HCC than those in chronic hepatitis or liver cirrhosis. The positive frequency of circulating IGF-Ⅱ mRNA was 34.2% in HCC, no amplified fragment was found in other liver diseases, extrahepatic tumors,and normal controls, respectively. The circulating IGF-Ⅱ mRNA correlated with the stage of HCC, and its positive rate was 100% in HCC with extrahepatic metastasis and 35.5% in HCC with AFP-negative. No significant correlation was found between tumor sizes and circulating IGF-Ⅱ mRNA fragment.CONCLUSION: The abnormal expressions of free IGF-Ⅱ and IGF-Ⅱ mRNA are useful tumor markers for HCC diagnosis, differentiation of extrahepatic metastasis and monitoring postoperative recurrence.
文摘目的检测特发性矮小症患儿血清25羟维生素D [25(OH)D]、胰岛素样生长因子-1 (IGF-1)水平,并探讨其与体质量的相关性,为患者的临床诊断提供指导。方法选取2017年1月至2019年6月期间广州市花都区妇幼保健院接诊的85例特发性矮小症患儿作为观察组,另选择同期在我院体检的50例儿童作为对照组。受检者入组后,空腹采集静脉血液标本,检测并比较两组患儿的25(OH)D、IGF-1水平、体质量和身高状况,并采用Spearman相关分析法分析25(OH)D、IGF-1、身高与体质量的相关性。结果观察组和对照组患儿的血清25(OH)D [(24.59±9.31) ng/mL vs (33.28±11.21) ng/mL]、IGF-1 [(237.16±37.33) ng/mL vs (309.35±71.52) ng/mL]、体质量[(15.67±2.01) kg/m2vs (18.42±1.65) kg/m2]、身高[(115.49±10.61) cm vs (138.35±10.09) cm]比较,观察组明显低于对照组,差异均具有统计学意义(P<0.05);观察组患儿的体质量与血清25(OH)D、IGF-1水平呈正相关(r=0.229、0.258,P<0.05),身高与血清25(OH)D、IGF-1水平也呈正相关(r=676、0.404,P<0.05)。结论特发性矮小症患儿血清25(OH)D、IGF-1水平均较低,且其与体质量和身高呈正相关,血清25(OH)D、IGF-1水平检测对特发性矮小症患儿的病情预测及防治都具有重要意义。
